Metastatic breast cancer drugs get PBS listings
Two new listings on the PBS target HER2-positive breast cancer, an aggressive subtype of the disease.
Pertuzumab, marketed as Perjeta, is approved for use in combination with trastuzumab and docetaxel for women who have not had prior treatment for metastatic disease. It targets the HER2 protein.
A trastuzumab-emtansine combination (marketed as Kadcyla) was also PBS-listed on July 1st.